In this issue:
Potential of WGS data linked to mortality statistics in breast cancer
Targeting dormant tumour cells to prevent recurrent breast cancer
Patritumab deruxtecan in hormone receptor+, HER2− advanced breast cancer
Weight loss intervention for women with stage II/III breast cancer
ILD with trastuzumab deruxtecan in real-world advanced breast cancer
Ki67 for predicting endocrine sensitivity in oestrogen receptor+, HER2– breast cancer
Xentuzumab-abemaciclib-endocrine therapy in advanced breast cancer
First-line zanidatamab-docetaxel in HER2-positive breast cancer
FES- vs. FDG-PET-CT in oestrogen receptor+ metastatic invasive lobular breast cancer
Acupuncture for hot flushes in breast cancer
Please login below to download this issue (PDF)